Is Enovis (ENOV) overvalued or fairly valued?

MarketChacha shows Enovis's valuation in context — a forward P/E of about 6.5, a price-to-book of about 1.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Enovis's revenue?

Enovis reported revenue of $2.2B for FY2025, with net profit of $-1.2B, per official filings.

What is the share price of Enovis (ENOV)?

Enovis last traded at $26.49 (-2.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Enovis

ENOV · NYSE · Healthcare · United States

$26.49-2.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:31 PM

Snapshot

TickerENOV

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees7,802

HeadquartersWilmington, United States

Market cap$1.5B

P/B1.0

Volume227.4K

Websitewww.enovis.com

Filings tracked3

About Enovis

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.6%
Institutions98.4%
Public & other0.0%

352 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.17.26%
American Century Companies Inc8.28%
Vanguard Portfolio Management LLC6.62%
Vanguard Capital Management LLC4.43%
Dimensional Fund Advisors LP4.42%
Rubric Capital Management LP4.26%
State Street Corporation4.17%
Davenport & Co LLC4.07%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 50.7 points over the period — profitability is trending down.

Net margin trend-1.9% → -52.7%

Margin has compressed by about 50.7 points over the period — profitability is trending down.

Return on equity-79.5%

Latest ROE of -79.5% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $562.0M · EPS 0.84

Est. earnings growth +12.0%

Next fiscal year

Rev $2.5B · EPS 4.08

Est. earnings growth +11.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$19.1452-wk range$34.28

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.5B

Day change

-2.3%

Fwd P/E

6.5

P/B

1.0

Beta

1.50

Revenue (FY2025)

$2.2B

Net margin

-52.7%

ROE

-79.5%

Revenue CAGR (2y)

+14.8%

EPS (FY2025)

-20.75

Net profit (FY2025)

$-1.2B

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ENOV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.2B	$-1.2B	-20.75	-52.7%	-79.5%
FY2024	$2.1B	$-825.5M	-14.93	-39.2%	-32.2%
FY2023	$1.7B	$-33.3M	-0.61	-1.9%	-1.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$589.2M	$-8.8M	-0.15	-1.5%
2025Q4	$548.9M	$-571.1M	-9.99	-104.1%
2025Q3	$564.5M	$-36.7M	-0.64	-6.5%
2025Q2	$558.8M	$-56.0M	-0.98	-10.0%
2024Q3	$505.2M	$-31.5M	-0.58	-6.2%
2024Q2	$525.2M	$-18.6M	-0.34	-3.5%
2024Q1	$516.3M	$-72.0M	-1.32	-13.9%
2023Q3	$417.5M	$-2.9M	-0.05	-0.7%
2023Q2	$428.5M	$-10.0M	-0.18	-2.3%
2023Q1	$406.2M	$-23.4M	-0.43	-5.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/19/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.